March 20, 2020 / 12:49 PM / 9 days ago

BRIEF-Mersana Therapeutics To Report Updated Data From The XMT-1536 Phase 1 Dose Escalation Study

March 20 (Reuters) - Mersana Therapeutics Inc:

* MERSANA THERAPEUTICS TO REPORT UPDATED DATA FROM THE XMT-1536 PHASE 1 DOSE ESCALATION STUDY

* MERSANA- REAFFIRMED PLANS TO HOST LIVE CONFERENCE CALL AND WEBCAST ON MAR 30 AT 5:00 P.M. ET TO REPORT DATA FROM XMT-1536 PHASE 1 DOSE ESCALATION STUDY Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below